- Trial phase
- Approved (FDA, June 17, 2026)
- Time to market
- Already approved (June 2026). US commercial launch expected by end of 2026.
- Why 4/10
- Utebzi was already FDA-approved on June 17, 2026, the defining binary catalyst has passed. No PDUFA, pivotal readout, or AdCom is scheduled in the next ~12 months. The drug is in early commercialization, where sales ramp, formulary wins, and payer decisions are gradual, non-binary events. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
Utebzi is already approved and launching, no binary catalyst remains. For GSK investors, this is a small positive for the anti-infectives portfolio but not a needle-mover. For SPRO, the $105M royalty monetization (July 2026) has already reduced the stock's direct sensitivity to Utebzi sales; the next major SPRO catalysts will be around the SP001 immunology program (Phase 2 start expected Q2 2027), not Utebzi.
Price Chart
Executive Summary
Utebzi (tebipenem pivoxil) is the first and only FDA-approved oral carbapenem antibiotic, cleared on June 17, 2026 as a Priority Review Type 1 New Molecular Entity for complicated urinary tract infections (cUTIs) in adults with limited or no alternative oral options. The drug was originated by Spero Therapeutics (SPRO) and is commercialized globally by GSK plc (LSE/NYSE: GSK) under an exclusive licensing deal. The pivotal PIVOT-PO Phase 3 trial demonstrated non-inferiority to IV imipenem-cilastatin. Because the approval binary has already passed and there is no pending regulatory decision, the stock-moving catalyst for this asset is behind us. For GSK, Utebzi is a modest pipeline addition to a ~$106.5B market-cap pharma giant. For SPRO, Utebzi provides a royalty stream, partially monetized via a $105M non-dilutive financing in July 2026, but the company has pivoted to immunology (SP001/IBI355), making near-term SPRO performance less dependent on Utebzi sales.
How It Works
Utebzi is an oral antibiotic from a powerful class called carbapenems (traditionally given only by IV in hospitals). It kills bacteria by blocking cell-wall construction, and being an oral pill allows patients with complicated UTIs to avoid hospitalization or switch from IV therapy to oral treatment at home. It is specifically designed for patients whose infections are resistant to standard oral antibiotics.
Trial Status
Approved based on the PIVOT-PO Phase 3 trial, which demonstrated non-inferiority of oral Utebzi versus IV imipenem-cilastatin in complicated UTIs. The drug received Priority Review and Type 1 (New Molecular Entity) classification from the FDA. Commercial launch expected in the US by end of 2026.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalyst for Utebzi, it is already approved and in early commercialization.
- For SPRO: Q2 2027 expected Phase 2 start for SP001 (anti-CD40L) in IgG4-RD, but this is unrelated to Utebzi.
- Utebzi sales figures in quarterly earnings reports (next likely Q3 2026 results), gradual commercial ramp, not a hard binary.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report